Text Size

Platelet Rich Plasma Study in Lower Extremity Bypass Surgery (PRP)

This study has been completed.
Sponsor:
Collaborator:
Biomet, Inc.
Information provided by:
Lawson Health Research Institute
ClinicalTrials.gov Identifier:
NCT00517452
First received: August 16, 2007
Last updated: January 4, 2011
Last verified: January 2011
History of Changes
  Purpose

The use of platelet rich plasma will decrease wound infection postop.


Condition Phase
Atherosclerosis
 Phase 2
Phase 3

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Phase 2-3 Observational Wound Care Study Comparing Application of Platelet Rich Plasma With Standard of Care Wound Closure in Vascular Patients Requiring a Groin Incision.

Resource links provided by NLM:

MedlinePlus related topics: Atherosclerosis
U.S. FDA Resources

Further study details as provided by Lawson Health Research Institute:

Primary Outcome Measures:
  • Wound healing [ Time Frame: 4- 6 weeks post op ] [ Designated as safety issue: No ]

Enrollment: 81
Study Start Date: May 2007
Study Completion Date: December 2007
Groups/Cohorts
Platelet Rich Plasma
Group received platelet rich plasma and observed over a period of 30 days or until wound closure
Standard Wound Care
Group was treated as per standard care

  Eligibility

Ages Eligible for Study:   35 Years to 90 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Vascular surgical patients scheduled for elective lower extremity bypass surgery,aortoiliac revascularizations and endovascular AAA repair requiring a groin incision

Criteria

Inclusion Criteria:

  • Vascular surgical patients scheduled for elective lower extremity bypass surgery,aortoiliac revascularizations and endovascular AAA repair requiring a groin incision Exclusion Criteria:Patients requiring emergent procedures, unable to give informed consent
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00517452

Sponsors and Collaborators
Lawson Health Research Institute
Biomet, Inc.
Investigators
Principal Investigator: Kirk D Lawlor London Health Sciences Centre, University of Western Ontario
  More Information

No publications provided

Responsible Party: Dr. K. Lawlor, Lawson Health Research Institute
ClinicalTrials.gov Identifier: NCT00517452     History of Changes
Other Study ID Numbers: R-07-098
Study First Received: August 16, 2007
Last Updated: January 4, 2011
Health Authority: Canada: Health Canada

Additional relevant MeSH terms:
Atherosclerosis
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases

ClinicalTrials.gov processed this record on May 23, 2013